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Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil
Analogs To Investigate the Function of P‑Glycoprotein in the Blood−
Brain Barrier
Renske M. Raaphorst,*,† Gert Luurtsema,‡ Robert C. Schuit,† Esther J. M. Kooijman,† Philip H. Elsinga,‡
Adriaan A. Lammertsma,† and Albert D. Windhorst†
†Department of Radiology & Nuclear Medicine, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
‡Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9712 CP
Groningen, The Netherlands
ABSTRACT: P-glycoprotein is an eﬄux transporter located in the blood−brain barrier. (R)-[11C]Verapamil is widely used as a
PET tracer to investigate its function in patients with epilepsy, Alzheimer’s disease, and other neurodegenerative diseases.
Currently it is not possible to use this successful tracer in clinics without a cyclotron, because of the short half-life of carbon-11.
We developed two new ﬂuorine-18 labeled (R)-verapamil analogs, with the beneﬁt of a longer half-life. The synthesis of (R)-N-
[18F]ﬂuoroethylverapamil ([18F]1) and (R)-O-[18F]ﬂuoroethylnorverapamil ([18F]2) has been described. [18F]1 was obtained in
reaction of (R)-norverapamil with the volatile [18F]ﬂuoroethyltriﬂate acquired from bromoethyltosylate and a silver trilate
column with a radiochemical yield of 2.7% ± 1.2%. [18F]2 was radiolabeled by direct ﬂuorination of precursor 13 and required
ﬁnal Boc-deprotection with TFA resulting in a radiochemical yield of 17.2% ± 9.9%. Both tracers, [18F]1 and [18F]2, were
administered to Wistar rats, and blood plasma and brain samples were analyzed for metabolic stability. Using [18F]1 and [18F]2,
PET scans were performed in Wistar rats at baseline and after blocking with tariquidar, showing a 3.6- and 2.4-fold increase in
brain uptake in the blocked rats, respectively. In addition, for both [18F]1 and [18F]2, PET scans in Mdr1a/b(−/−), Bcrp1(−/−), and
WT mice were acquired, in which [18F]2 showed a more speciﬁc brain uptake in Mdr1a/b(−/−) mice and no increased signal in
Bcrp1(−/−) mice. [18F]2 was selected as the best performing tracer and should be evaluated further in clinical studies.
KEYWORDS: P-gp, BCRP, positron emission tomography, blood−brain barrier, verapamil, 18F, ABC transporters
■ INTRODUCTION
The blood−brain barrier (BBB) is a diﬀusion barrier between
the central nervous system and the circulation that protects the
brain from entrance of neurotoxic substances. Endothelial cells
with tight junctions prevent paracellular passage. Transcellular
passage is possible by selective transport of, for example, amino
acids, vitamins, and sugars via their speciﬁc transporters.1 ATP-
binding cassette (ABC) transporters constitute an important
transporter family at the BBB with the most investigated ones
being P-glycoprotein (P-gp/ABCB1) and breast cancer
resistance protein (BCRP/ABCG2). Both are ATP dependent
eﬄux transporters, mediating the transport of structurally
diverse compounds from brain to blood, and share some
substrates. Research supports that P-gp function is diminished
in Alzheimer’s disease, causing accumulation of β-amyloid, in
the brain.2 On the other hand, several studies have shown
increased P-gp function in epilepsy patients, causing drug
resistance.3 A number of studies have used positron emission
tomography (PET) to investigate the function of P-gp with
radiolabeled substrates. The most widely used PET tracer for P-
gp is [11C]verapamil, originally a calcium channel blocker, but
also a substrate of P-gp.4 In early studies, it was used as a
racemic mixture, but later it was shown that the (R)-enantiomer
had better in vivo stability than the (S)-isomer and the use of a
single isomer is essential for quantiﬁcation of P-gp function.5 In
a clinical PET study using (R)-[11C]verapamil, (mild) AD
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patients showed 50% reduced P-gp function in brain regions
related to AD compared with healthy, age-matched controls.6
Although (R)-[11C]verapamil has shown its usefulness in
clinical research, it has several drawbacks. Metabolite studies
have shown that N-dealkylation of the parent compound results
in the radiolabeled metabolite [11C]D617, which turned out to
be a P-gp substrate as well. Metabolite formation could disturb
the PET image when the radiolabeled metabolites interact with
P-gp in a diﬀerent manner than the parent compound and
makes quantiﬁcation challenging. To circumvent this problem,
[11C]D617 itself was investigated as a P-gp tracer.7 In vivo
studies, however, showed lower aﬃnity of [11C]D617 for P-gp
than (R)-[11C]verapamil, and therefore it was not a satisfactory
substitute. The aspect of (R)-[11C]verapamil the we want to
tackle is the use of the isotope carbon-11, with the short half-
life of 20 min. Although, the rapidly decaying isotope gives the
opportunity for multiple PET scans in 1 day with the same
object, it is only possible to perform studies with the PET tracer
at a facility in close proximity to a cyclotron. A ﬂuorine-18
labeled PET tracer would give the opportunity to investigate P-
gp in almost all facilities in possession of a PET scanner.
Besides transport, a longer half-life gives the opportunity for
longer scan time and multiple patient batches out of one tracer
production. The energy of the positron emission of ﬂuorine-18
is lower compared with carbon-11 and results in a lower range
and better resolution of the PET image.
Recently, some new ﬂuorine-18 labeled P-gp PET tracers
have been developed. [18F]Geﬁtinib, originally an epidermal
growth factor receptor inhibitor and a substrate for P-gp and
BCRP,8 was used in a study to examine drug−drug interactions
at the BBB. However, again this is not a speciﬁc P-gp tracer,
since it is also transported by BCRP.9 In another
comprehensive study of Sander et al., ﬂuorine-18 labeled
tracers were used in a new approach to metabolically activate a
dual P-gp/BCRP substrate. Although the proof-of-concept was
successful, slow rates of enzymatic conversion toward the
prodrug tracer did not give the anticipated results.10 Another
study proposed three new ﬂuorine-18 labeled P-gp tracers.
Only one of the three showed P-gp substrate functionality in
vivo, although all tracers were evaluated as substrates in
vitro.11,12
While these studies are all attempts to label a substrate of P-
gp, to image the expression levels of P-gp in relevant brain
regions, an inhibitor of binding ligand is needed. Two ﬂuorine-
18 labeled P-gp tracers were based on analogs of the P-gp
inhibitors tariquidar and elacridar. 1-[18F]Fluoroelacridar
showed excessive deﬂuorination in vivo and was not further
developed.13 [18F]Fluoroethylelacr idar and [18F]-
ﬂuoroethyltariquidar showed P-gp substrate behavior in vivo,
with a small increase in brain uptake for Mdr1a/b(−/−) mice but
much higher uptake for Mdr1a/b(−/−)Bcrp1(−/−) mice, indicat-
ing that they were substrates for both P-gp and BCRP.14
Therefore, the tracers could not be used for the intended
purpose of quantiﬁcation of P-gp function.
To date, no ﬂuorine-18 labeled P-gp tracer is available for
clinical use. Since (R)-[11C]verapamil has shown its value in
multiple clinical studies, the purpose of the present study was to
investigate two novel ﬂuorine-18 analogs of verapamil, (R)-N-
[18F]ﬂuoroethylverapamil ([18F]1) and (R)-O-[18F]-
ﬂuoroethylnorverapamil ([18F]2), as tracers of P-gp function.
■ RESULTS AND DISCUSSION
Chemistry. The aim of this study was to develop a new
ﬂuorine-18 labeled P-gp substrate; therefore two verapamil
analogs containing a ﬂuoroethyl group were investigated. The
two diﬀerent positions of the ﬂuoroethyl group were chosen in
order to investigate the eﬀect on pharmacokinetics and
metabolism. For [18F]1, the ﬂuoroethyl group was placed on
the original position of the [11C]methyl group on the amine.
To make [18F]2 less prone to metabolism, one of the methoxy
groups was replaced with the ﬂuoroethyl group, keeping in
mind that the average bond enthalpy between a C−O bond is
Scheme 1. Metabolic Pathway of [11C]Verapamil as Adapted from Luurtsema et al.18a
aThe two proposed P-gp PET tracers with likely positions for metabolic cleavage are depicted at the bottom of the schematic.
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higher and therefore stronger than a C−N bond.15 The
metabolic pathway of [11C]verapamil has been studied
thoroughly16 and its main metabolite is norverapamil, with
the [11C]methyl group cleaved oﬀ resulting in polar radioactive
metabolites (Scheme 1). In addition, the formed metabolite
[11C]D617 of [11C]verapamil, was proven to be a substrate of
P-gp,7 and it is assumed that the 18F-analog of D617 would also
act as a substrate of P-gp. The formation of radioactive
metabolites could provide a background signal (of unknown
amount) to the PET images and, therefore, make quantitative
interpretation of PET data diﬃcult if not impossible. To
circumvent these issues, the [18F]ﬂuoroethyl group was placed
on the phenol that is not part of D617, at the same time
removing the methyl group on the amine to avoid the ﬁrst
metabolic step toward norverapamil, since this is a substrate of
P-gp as well.17
It is known that the (R)-enantiomer of verapamil is less
prone to metabolism, has lower aﬃnity for the calcium channel,
and shows better pharmacokinetics than the (S)-enan-
tiomer.5,19 Therefore, the (R)-enantiomer of the precursor
and reference compound of [18F]2 were synthesized. To avoid
the use of expensive starting materials or chiral HPLC
puriﬁcation, the method of Gilmore et al. was used20 (Schemes
2 and 3). Using this method, the (R,S/R,R)-diastereomer
intermediate 10 was synthesized, which enables stereochemical
puriﬁcation by ﬂash column chromatography in batches up to
multiple grams. After puriﬁcation of the (R,R)-intermediate,
acidic hydrolysis, and periodate cleavage of the resulting diol,
gave (R)-aldehyde 11. Elongation of aldehyde 11 was executed
through a Wittig reaction followed by acidic hydrolysis to (R)-
aldehyde 12. The second diﬃculty occurred during the
reductive amination between obtained (R)-aldehyde 12 and
amine 7. The secondary amine was formed, but could not be
puriﬁed. The reaction did not proceed eﬃciently due to
formation of a byproduct by intermolecular substition, with
tosylate acting as leaving group to form a dimer, as identiﬁed by
MS. To prevent this undesirable side reaction, the Boc
protection was carried out immediately after workup of the
reductive amination, without reducing the volume of solvent.
With a yield of 44% over the reductive amination and Boc
protection, this is a viable method to synthesize (R)-precursor
13. The reference compound 2 was synthesized from aldehyde
12 and amine 8 containing the ﬂuoroethoxy group.
Scheme 2a
aReagents and conditions: (a) Boc2O, Et3N, MeOH, r.t., 2 h; (b) synthesis of 5, ethylene di(p-toluenesulfonate), K2CO3, KI, DMF, rt, 3 h; synthesis
of 6, 1-bromo-2-ﬂuoroethane, K2CO3, KI, DMF, 75 °C, 18 h; (c) TFA, DCM, rt, 1 h.
Scheme 3a
aReagents and conditions: (a) NaH, DMF, 65 °C, 3 h, (R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl 4-methylbenzenesulfonate, 65 °C, 18 h, ﬂash
column chromatography; (b) AcOH, H2O, rt, 18 h; (c) NaIO4, NaHCO3, CH2Cl2, rt, 4 h; (d) MeOCHPPh3, THF, −80 °C to rt, 4 h;
subsequently, p-TSA, i-PrOH, H2O, 80 °C, 3 h; (e) synthesis of 2, 8, NaBH(OAc)3, Na2SO4, MeOH, rt, 18 h; synthesis of 10, (i) 7, NaBH(OAc)3,
Na2SO4, DCE, rt, 18 h; (ii) Boc2O, Et3N, EtOAc, rt, 1.5 h.
Scheme 4a
aReagents and conditions: (a) 18F/K2.2.2/K
+, DMF, 90 °C, 15 min; (b) AgOTf, 200 °C, 15 min; (c) [18F]ﬂuoroethyltriﬂate, K2CO3, MeCN, 120 °C,
15 min.
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The precursor of [18F]1, (R)-norverapamil (17), was kindly
donated by Abbott Laboratories, and therefore the synthesis of
the reference compound of [18F]1 was straightforward. (R)-
Norverapamil (17) was alkylated with 1,2-bromoﬂuoroethane
to obtain reference compound 1.
Radiochemistry. Although its precursor was readily
available, the radiochemical synthesis of [18F]1 was more
challenging. Radiolabeling of (R)-norverapamil to obtain [18F]1
was ﬁrst pursued by ﬂuorinating bromoethyltosylate to give
bromo[18F]ﬂuoroethane ([18F]15), which was distilled into a
second vial containing a solution with 3 mg of (R)-
norverapamil (17) and 1.6 mg of K2CO3 that was heated to
120 °C in MeCN. However, for the second step, only 0.5%
conversion was observed on HPLC. Therefore, a silver triﬂate
oven was introduced to conduct volatile bromo[18F]-
ﬂuoroethane conversion into [18F]ﬂuoroethyltriﬂate ([18F]
16), substituting the bromine for a stronger leaving group,
and this intermediate was bubbled through the precursor
solution (Scheme 4). This resulted in higher conversion, and
when the solution was also stirred to improve solubility of
K2CO3, the ﬁnal reaction conditions were achieved, resulting in
an overall yield of 2.4% ± 1.4%, a speciﬁc activity of 143 ± 88
GBq/μmol, and a radiochemical purity of >99%. The yield of
[18F]1 was still lower than expected, which is mainly caused by
poor trapping of activity in the second reaction vial after
distillation. Nevertheless, suﬃcient activity was obtained for
preclinical studies. For [18F]2, the precursor synthesis was
designed to prevent this problem by addition of a tosyl group
for direct ﬂuorination, followed by Boc-deprotection (Scheme
5). No optimization was required for animal experimentation,
and the overall yield was 14.3% ± 6.8%, with a speciﬁc activity
of 151 ± 74 GBq/μmol and a radiochemical purity of >99%.
Biodistribution. The biodistribution of [18F]1 in Wistar
rats shows a relatively slow washout from the blood pool and
other related organs and low brain uptake, presumably caused
by the eﬄux transport of P-gp (Figure 1). Since bone uptake
was low and did not increase over time, deﬂuorination of the
tracer appears to be absent. Diﬀerent behavior in rats was
observed for [18F]2, with lower brain uptake (compared with
[18F]1) and high initial uptake in kidney and lung, which
decreases over time. This is similar to the biodistribution of
[11C]verapamil.21 In some cases, high lung uptake can be
explained by perfusion, which is related to the activity in
plasma. However, the blood values for [18F]2 are even lower
than [18F]1; therefore this could not be concluded. [18F]2 is
not prone to deﬂuorination based on its low bone uptake.
Metabolite Analysis. Metabolite analyses of both tracers
were performed in healthy Wistar rats, 5, 15, and 60 min after
tracer injection, and the results are shown in Table 1. For both
tracers, the parent tracer was found in the nonpolar fraction and
was identiﬁed by HPLC. The metabolite analysis showed a
rapid rate of metabolism in rats for both PET tracers. The main
metabolite fraction was the polar metabolites. Since bone
uptake is not observed in the PET scans (vide inf ra) and
biodistributions, the polar metabolites are not products of
deﬂuorination. Therefore, the high polar fraction consists of
metabolites most likely formed via cleavage of the ﬂuoroethyl
group.
For [18F]1, the metabolic pathway is expected to be similar
to [11C]verapamil, which gives norverapamil as the main
Scheme 5a
aReagents and conditions: (a) 18F/K2.2.2/K
+, MeCN, 90 °C, 5 min; (b) TFA, 20 °C, 10 min.
Figure 1. Biodistribution of [18F]1 and [18F]2 in selected organs. Data are expressed as percentage injected dose per gram tissue (%ID/g).
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metabolite, next to polar monocarbon labeled ones like
[11C]formaldehyde, [11C]formic acid, and [11C]carbon dioxide
(Scheme 1). The high polar fraction observed in the metabolite
analysis of [18F]1 indicates that the [18F]ﬂuoroethyl group is
even more prone to metabolism than the [11C]methyl group,
resulting in [18F]ﬂuoroacetaldehyde, and other small oxidized
fractions. Furthermore, a peak likely corresponding to [18F]-
ﬂuoroethyl labeled D617 was observed in the nonpolar fraction
on HPLC. This presumably can act as a substrate of P-gp,
similar to [11C]D617, which could interfere with the PET signal
when it interacts with P-gp in a diﬀerent matter than the parent
tracer.
With this in mind, it was expected that [18F]2 would show a
lower rate of metabolism, since this ﬁrst metabolic step is
avoided by eliminating the amine bound methyl group in the
designed structure. However, this eﬀect was not observed, and
high polar fractions were measured. Possible enzyme cleavage
sites are the [18F]ﬂuoroethyl group and the amine bound alkyl
groups, with the latter being less sterically hindered in the
secondary amine compared with a tertiary amine (Scheme 1).
Labeled metabolites will not be analogs of D617, since that part
of the molecule was not labeled with ﬂuorine-18. Therefore, it
is unlikely that labeled metabolites are substrates of P-gp.
It was shown that metabolism of [11C]verapamil was less
rapid in humans compared with rats. While only 28.1% ± 2.7%
of the total activity in the rat plasma was parent tracer at 60
min,18 in humans it was 45% ± 9%.22 Therefore, we anticipate
that while tracers [18F]1 and [18F]2 are metabolized rapidly in
rats, in humans this will likely be slower but must be monitored
during the translation of these tracers to humans.
P-gp Blocking Study with Tariquidar. Rats were treated
with P-gp inhibitor tariquidar 30 min before injection of [18F]1
or [18F]2, a method in line with previous reports studying P-gp
in rats.23 Brain uptake of [18F]1 was 3.6-fold higher than in the
baseline scans (Figure 2a). The highest brain uptake was at 5
min. For [18F]2, a 2.4-fold higher brain uptake was observed in
tariquidar treated animals compared with baseline brain uptake
(Figure 2b). However, a diﬀerence was observed in
pharmacokinetics between the two tracers. While behavior of
[18F]1 was similar to that of verapamil, with an injection peak
followed by washout over time, [18F]2 showed no injection
peak, while both tracers were injected via a comparable bolus
injection. Instead, a more steady time activity curve of [18F]2
resulted in higher activity levels at the end of the scan. It is
likely that this diﬀerence is caused by the higher polarity of
[18F]2, due to the secondary amine, as compared with the
tertiary amine of [18F]1. This could lead to more diﬃcult and
thus slower passive diﬀusion of [18F]2 through the BBB and
therefore delayed interaction with P-gp. This is supported by
the measured log D values of 2.08 and 1.61 for [18F]1 and [18F]
2, respectively.
PET Imaging in Mdr1a/b(−/−) and Bcrp1(−/−) Mice. Given
that, at a dose of 15 mg/kg, tariquidar is known to be an
inhibitor of both P-gp and BCRP,24,25 another PET study using
knockout animals was performed to assess the speciﬁcity of the
two tracers (Figure 3). To enable a direct comparison, a similar
study was performed using (R)-[11C]verapamil (Figure 4).
Unfortunately, as the HRRT scanner had just been
decommissioned, the [18F]2 study in Mdr1a/b(−/−) mice vs
wild-type (WT) mice was performed using new PET/CT and
PET/MR small animal scanners. This led to slightly diﬀerent
results for the wild-type animals, compared with the Bcrp1(−/−)
vs wild-type mice study, probably due to diﬀerences in spatial
resolution. Therefore, TACs are presented separately in Figure
3a−d. Figure 3e,f represents the ratio of brain uptake in Mdr1a/
b(−/−)/WT and Bcrp1(−/−)/WT for both [18F]1 and [18F]2,
respectively, to normalize for the scanner diﬀerences.
For both tracers, no signiﬁcant diﬀerences in brain uptake
were observed between wild-type and Bcrp1(−/−) mice,
indicating that neither are BCRP substrates (Figures 3c,d).
Both tracers showed increased brain uptake in Mdr1a/b(−/−)
mice (Figures 3a,b). A smaller diﬀerence in brain uptake was
noticed for [18F]1, with only a 1.4-fold higher brain uptake
during the ﬁrst 10 min compared with wild-type mice. This is
mainly due to high uptake in the wild-type animals, which
Table 1. [18F]1 and [18F]2 and Their Radiolabeled
Metabolites in Plasma and Brain Tissuea in Wistar rats
[18F]1 [18F]2
min plasma brain plasma brain
parent tracer 5 46 ± 14 41 ± 10 20 ± 3 26 ± 6
15 19 ± 2 14 ± 2 8 ± 3 17 ± 7
60 3 ± 1 2 ± 0.3 4 ± 1 6 ± 1
nonpolar metabolites 5 5 ± 2 5 ± 3
15 9 ± 3 5 ± 1
60 5 ± 1 3 ± 1
polar metabolites 5 49 ± 11 75 ± 3
15 71 ± 2 87 ± 1
60 92 ± 1 93 ± 2
Brain metabolites 5 59 ± 10 74 ± 6
15 86 ± 2 83 ± 7
60 98 ± 0.3 94 ± 1
aPercentage of total radioactivity, mean ± SD.
Figure 2. Whole brain time−activity curves of [18F]1 and [18F]2 in Wistar rats at (●) baseline and (■) after treatment with tariquidar (15 mg/kg).
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suggests that [18F]1 is a poorer tracer of P-gp (Figure 3e) than
[18F]2. For [18F]2, uptake in wild-type mice was similar to that
of [11C]verapamil. Although metabolism of [18F]2 was even
more rapid than that of [18F]1, [18F]2 in Mdr1a/b(−/−) mice
showed steady brain uptake up to a 6.4-fold higher level than
that in wild-type mice, reaching a SUV plateau of about 0.9 at
the end of the scan. The slower increase in brain uptake could
be due to the lower log D value and therefore diﬃculty in
crossing the BBB. The irreversible kinetics of [18F]2 are in
general not ideal for PET analysis. In this study, no blood
samples were collected from mice; therefore kinetic modeling
was not possible. To obtain more insight in the relationship
between the activity concentration in the blood and total brain
uptake, blood data was collected from the scans.
Figure 3. Time−activity curves of whole brain uptake of [18F]1 and [18F]2 in (●) wild-type (WT) mice, (■) Bcrp1(−/−) mice, or (▲) Mdr1a/b(−/−)
mice. [18F]1 in (a) WT vs Mdr1a/b(−/−), (c) WT vs Bcrp1(−/−), (e) ratio of both Mdr1a/b(−/−) and Bcrp1(−/−) over WT; [18F]2 in (b) WT vs
Mdr1a/b(−/−), (d) WT vs Bcrp1(−/−), (f) ratio of both Mdr1a/b(−/−) and Bcrp1(−/−) over WT.
Figure 4. (a) Time−activity curve of whole brain uptake of [11C]verapamil in (●) wild-type (WT) mice (n = 2), (■) Bcrp1(−/−) mice (n = 3), or
(▲) Mdr1a/b(−/−) mice (n = 2). (b) Ratio of both Mdr1a/b(−/−) and Bcrp1(−/−) over WT.
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As shown in Table 2, both [18F]1 and [18F]2 showed a
higher brain-to-blood AUC ratio in Mdr1a/b(−/−) mice
compared with WT animals. However, [18F]1 also showed an
increased brain-to-blood ratio in Bcrp1(−/−) mice. Since both
compounds are close analogs of (R)-[11C]verapamil, which is a
P-gp speciﬁc PET tracer, the dual P-gp/Bcrp PET tracer
behavior of [18F]1 is an unexpected observation.
In the case of [18F]2, brain-to-blood AUC ratios were
statistically signiﬁcant (P < 0.05, Student’s t test for paired data)
for Mdr1a/b(−/−) vs WT and Mdr1a/b(−/−) vs Bcrp(−/−)
animals. This was not the case for [18F]1 where the diﬀerence
between Mdr1a/b(−/−) vs WT mice and Bcrp(−/−) vs WT mice
were signiﬁcant but not that between Mdr1a/b(−/−) vs Bcrp(−/−)
animals.
The high Mdr1a/b(−/−)/WT ratio of [18F]2 over 60 min
(Figure 3f) shows a speciﬁc P-gp substrate at the same ratio of
(R)-[11C]verapamil, which is conﬁrmed by the signiﬁcant
diﬀerences of the brain-to-blood AUC ratios, despite the rapid
rate of metabolism from the previous analysis (Table 1).
Possible explanations are diﬀerences in expression of P-gp
between species and the rate of metabolism in rats vs
mice.18,26,27 Another explanation of the stable TAC pattern of
[18F]2 is found in the similarity with [11C]dLop, another P-gp
PET tracer, which was shown to be caused by acidic lysosomal
trapping in the brain. This is possible for more basic
radiotracers, like [18F]2 with the secondary amine, that have
the ability to diﬀuse into lysosome and subsequently be
protonated in the acid lysosomal interior.28 A third possibility is
the eﬀect of anesthesia on the diﬀerent species and the diﬀerent
time frames (repeated anesthesia in rats vs one time anesthesia
in mice), which was not examined. However, in a paper of
Wanek et al., mice were tested with (R)-[11C]verapamil under
long and short periods of time (160 and 5 min, respectively)
under anesthesia, and no signiﬁcant eﬀect was observed.27
While this behavior is not fully explained for [18F]2, it does
show speciﬁc brain uptake in Mdr1a/b(−/−) mice supporting its
potential use as P-gp PET tracer.
■ CONCLUSION
Both PET tracers showed substrate behavior in tariquidar
treated rats with diﬀerent patterns over time. While [18F]1
showed higher initial uptake followed by faster washout, [18F]2
showed slower brain uptake. As tariquidar is an inhibitor of
both BCRP and P-gp, the PET study in knockout mice showed
that [18F]2 was more speciﬁc for P-gp, despite its fast rate of
metabolism. As the rate of metabolism is species dependent,
further studies in humans are needed to assess the potential of
[18F]2 as a clinical PET tracer.
■ METHODS
General. Chemicals and solvents were purchased from commercial
sources, Sigma-Aldrich (Zwijndrecht, the Netherlands), Fluorochem
(Hadﬁeld Derbyshire, UK), ABCr GmbH (Karlsruhe, Germany), and
Biosolve (Valkenswaard, the Netherlands), without further puriﬁcation
unless stated otherwise. (R)-Desmethyl-verapamil was kindly donated
by Abbott Laboratories (IL, USA). Dichloromethane (DCM),
dichloroethane (DCE), methanol (MeOH), and dimethylformamide
(DMF) were dried over 3 Å molecular sieves for at least 24 h prior to
use. Tetrahydrofuran (THF) was ﬁrst distilled from LiAlH4 and then
dried over 3 Å molecular sieves. Thin layer chromatography (TLC)
was performed on Merck (Darmstadt, Germany) precoated silica gel
60 F254 plates. Spots were visualized by UV quenching or ninhydrin.
Column chromatography was carried out either manually by using
silica gel 60 Å (Sigma-Aldrich) or on a Buchi (Flawil, Switzerland)
sepacore system (comprising a C-620 control unit, a C-660 fraction
collector, 2 C601 gradient pumps, and a C640 UV detector) equipped
with Buchi sepacore prepacked ﬂash columns. 1H and 13C nuclear
magnetic resonance (NMR) spectra were recorded on a Bruker
(Billerica, USA) Avance 500 (500.23 and 125.78 MHz, respectively)
with chemical shifts (δ) reported in ppm relative to the solvent.
Electrospray ionization mass spectrometry (ESI-MS) was carried out
using a Bruker microTOF-Q instrument in positive ion mode
(capillary potential of 4500 V). QC analysis was performed using an
HPLC system of Jasco (Easton, MD, USA) containing a PU-2089
pump station equipped with a Varian Kromasil C18 column (10 μm,
250 mm × 4.6 mm, EKA Chemicals AB or AkzoNobel, Sweden) using
H2O/MeCN/diisopropanolamine (DIPA) (40:60:0.2, v/v/v, method
A) as eluent or Grace Alltima C18 column (5 μm, 250 mm × 4.6 mm,
Grace, Columbia, USA) using H2O/MeCN/DIPA (40:60:0.2, v/v/v,
method B) or H2O/MeCN/TFA (60:40:0.2, v/v/v, method C) or
H2O/MeCN/TFA (30:70:0.2, v/v/v, method D (intermediate)) as
eluent at a ﬂow rate of 1 mL·min−1, with a Jasco UV-2075 UV detector
(λ = 232 nm) and a NaI radioactivity detector (Raytest, Straubenhardt,
Germany). Chromatograms were acquired using Raytest GINA Star
software (version 5.01). Semipreparative HPLC was performed on a
Jasco PU-2089 pump station equipped with Luna C18(2) column (10
μm, 250 mm × 10 mm, Phenomenex, California, USA) using 5 mM
K3PO4/MeCN (28:72, v/v, pH = 10.0 method E) or H2O/MeCN/
TFA (60:40:0.2, v/v/v, method F) as eluent at a ﬂow rate of 4 mL·
min−1, a Jasco UV-1575 Plus UV detector (λ = 254 nm), a custom-
made radioactivity detector, and Jasco ChromNAV CFR software
(version 1.14.01) for data acquisition. Metabolite analysis was
performed on Dionex (Sunnyvale, CA, USA) UltiMate 3000 HPLC
equipment with Chromeleon software (version 6.8). A LUNA C8 (5
μm, 250 mm × 10 mm, Phenomenex) column was used (method F)
using 5 mM NH4OAc/MeCN (1:1, v/v, pH = 4.2) as eluent at a ﬂow
rate of 3.5 mL/min.
Chemistry. (R)-2-(3,4-Dimethoxyphenyl)-2-(((R)-2,2-dimethyl-
1,3-dioxolan-4-yl)methyl)-3-methylbutanenitrile (10). To a stirred
solution of 2-(3,4-dimethoxyphenyl)-3-methylbutanenitrile (9, 3.83 g,
17.5 mmol) in 60 mL of dry DCM was added sodium hydride (60%
dispersion in mineral oil; 1.40 g, 34.9 mmol), and the mixture was
heated to 65 °C. After 3 h, the reaction mixture was cooled to room
temperature, (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methyl-
benzenesulfonate (5.00 g, 17.5 mmol) dissolved in 5 mL of dry
THF was added, and the reaction mixture was stirred at 65 °C
overnight. The dark brown mixture was quenched with water and
extracted into diethyl ether, organic layers were washed with water and
brine and dried over Na2SO4, and the solvent was evaporated in vacuo.
The crude product was puriﬁed by ﬂash column chromatography (10−
30% EtOAc/hexane) to yield the R,R-diastereomer 10 (3.96 g, 11.9
mmol, 68.1% yield) as a light brown oil. 1H NMR (CDCl3) δ 6.95−
6.83 [3H, m, CHAR], 4.03−3.92 [1H, m, CHO], 3.89 [3H, s, CH3O],
3.90 [3H, s, CH3O], 3.19 [1H, dd, J = 5.6 and 8.3 Hz, CH2O], 2.98
[1H, t, J = 7.9 Hz, CH2O], 2.65 [1H, dd, J = 4.6 and 13.8 Hz,
CH2CHO], 2.15 [1H, sept, J = 6.7 Hz, CH(CH3)2], 1.90 [1H, dd, J =
7.7 and 13.6 Hz, CH2CHO], 1.36 and 1.26 [3H each, s, C(CH3)2],
1.23 and 0.79 [3H each, d, J = 6.7 Hz, CH(CH3)2];
13C NMR
(CDCl3) δ 149.12, 148.71, 129.9, 120.47, 118.6, 111.19, 109.53,
108.14, 73.7, 69.34, 56.06, 55.92, 51.1, 42.38, 37.92, 26.78, 25.72, 18.6,
18.52; ESI-HRMS calculated for C19H27NO4 333.1940, found
334.2058 [M + H]+, 356.1898 [M + Na]+.
Table 2. Brain-to-Blood AUC Ratios
groups brain-to-blood AUC ratios
[18F]1 WT 0.52 ± 0.05
Mdr1a/b(−/−) 0.98 ± 0.07
Bcrp1(−/−) 0.88 ± 0.06
[18F]2 WT 0.18 ± 0.04
Mdr1a/b(−/−) 0.75 ± 0.14
Bcrp1(−/−) 0.20 ± 0.02
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lan-4-yl)methyl)-3-methylbutanenitrile (10, 847 mg, 2.54 mmol) was
dissolved in water (4 mL) and acetic acid (12 mL) and stirred at room
temperature overnight. The volume was reduced by evaporation,
giving the crude diol as a colorless oil. The crude reaction mixture was
dissolved in DCM (35 mL), and 1 M NaHCO3 (16.9 mL, 16.9 mmol)
was added. To the stirred biphasic system was added a solution of
sodium periodate (2.20 g, 10.3 mmol) in water (11 mL) dropwise over
2 h. The white suspension was stirred for another 2 h. The suspension
was diluted with DCM, and the organic phase was separated, washed
with water, and dried over Na2SO4, and the solvent was evaporated in
vacuo. The resulting brown oil was puriﬁed by ﬂash column
chromatography (25% EtOAc/Hex) to obtain (R)-2-(3,4-dimethox-
yphenyl)-2-isopropyl-4-oxobutanenitrile, 11 (434 mg, 1.66 mmol,
65.4% yield), as a colorless oil. 1H NMR (CDCl3) δ 6.93−6.84 [3H,
m, CHAR], 3.90 [3H, s, OCH3], 3.88 [3H, s, OCH3], 3.14−2.87 [2H,
m, CH2CHO], 2.14 [1H, sept, J = 6.7 Hz, CH(CH3)2], 1.18 and 0.89
[3H each, d, J = 6.7 Hz, CH(CH3)2];
13C NMR (CDCl3) δ 149.35,
148.93, 128.75, 120.45, 118.81, 111.35, 109.70, 56.09, 55.95, 49.80,
48.66, 38.19, 18.43, 18.22; ESI-HRMS calculated for C15H19NO3
261.1365, found 262.1458 [M + H]+ and 284.1285 [M + Na]+.
(R)-2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-oxopentanenitrile
(12). (Methoxymethyl)triphenylphosphonium chloride (3.33 g, 9.71
mmol) was suspended in THF (50 mL) and brought to −50 °C, and
n-butyllithium (1.6 M in hexanes; 12.1 mL, 19.4 mmol) was added
dropwise via a dropping funnel over 30 min, stirring for 1 h at −80 °C.
To the resulting dark red solution, (R)-2-(3,4-dimethoxyphenyl)-2-
isopropyl-4-oxobutanenitrile (11, 705 mg, 2.70 mmol) dissolved in 4
mL of THF was added dropwise over 15 min, and the mixture was
stirred for 2 h at −80 °C and slowly brought to rt. The reaction was
quenched with water and extracted with Et2O. The organic layers were
washed with water and brine and dried over Na2SO4, and the solvent
was evaporated in vacuo. The crude oil was puriﬁed by ﬂash column
chromatography (5−20% EtOAc/Hex) to obtain a mixture of the E/
Z-isomers of the desired intermediate (356 mg, 1.23 mmol, 45.6%
yield). To a solution of (R)-2-(3,4-dimethoxyphenyl)-2-isopropyl-5-
methoxypent-4-enenitrile (356 mg, 1.23 mmol) in 2-propanol (3 mL)
and water (3 mL), 4-methylbenzenesulfonic acid hydrate (14.0 mg,
0.074 mmol) was added, and the mixture was stirred to reﬂux for 3 h.
The reaction was quenched with water and extracted with Et2O. The
organic layers were washed with 1 M NaHCO3 and brine and dried
over Na2SO4, and the solvent was evaporated in vacuo. The crude oil
was puriﬁed with ﬂash column chromatography (10% EA in hexane)
obtaining the preferred product 12 (95 mg, 0.35 mmol, 28% yield). 1H
NMR (CDCl3) δ 6.94−6.82 [3H, m, CHAR], 3.89 [6H, m, (OCH3)2],
2.70−2.40 [2H, m, CH2CH2CHO], 2.24−2.06 [3H, m, CH(CH3)2
and CH2CHO], 1.22 and 0.81 [3H each, d, J = 6.7 Hz, CH(CH3)2];
13C NMR (CDCl3) δ 200.44, 149.22, 148.58, 129.58, 120.80, 118.69,
111.19, 109.21, 56.03, 55.93, 52.67, 40.60, 38.00, 29.92, 19.06, 18.60;
ESI-HRMS calculated for C16H21NO3 275.1521, impossible to ionize.
tert-Butyl 4-Hydroxy-3-methoxyphenethylcarbamate (4). Trie-
thylamine (0.42 mL, 3.0 mmol) and di-tert-butyl dicarbonate (0.69
mL, 3.0 mmol) dissolved in 3 mL of methanol were added to a
solution of 4-(2-aminoethyl)-2-methoxyphenol (3) (500 mg, 2.99
mmol) in 10 mL of methanol and stirred for 2 h at 50 °C. The solvent
was evaporated in vacuo, and the crude product was extracted with
EtOAc, washed with water and brine, and dried over Na2SO4, and the
solvent was evaporated in vacuo. The white crystallized solid obtained
was puriﬁed using ﬂash column chromatography (1−5% MeOH/
DCM) resulting in the desired product as a clear oil (460 mg, 1.72
mmol, 57.5% yield). 1H NMR (CDCl3) δ 6.87−6.66 [3H, m, CHAR],
4.54 [1H, bs, OH], 3.88 [3H, s, OCH3], 3.34 [2H, q, J = 6.4 Hz,
NHCH2], 2.72 [2H, t, J = 7.1 Hz, NHCH2CH2], 1.44 [9H, s,
C(CH3)3];
13C NMR (CDCl3) δ (ppm) 158.49, 148.9, 145.96, 132.15,
122.32, 116.21, 113.47, 80.02, 56.39, 43.4, 36.89, 28.92; ESI-HRMS
calculated for C14H21NO4 267.1471, found 290.1328 [M + Na]
+.
tert-Butyl 4-(2-Fluoroethoxy)-3-methoxyphenethylcarbamate
(6). tert-Butyl 4-hydroxy-3-methoxyphenethylcarbamate (4, 309 mg,
1.16 mmol), 1-bromo-2-ﬂuoroethane (0.345 mL, 4.62 mmol), K2CO3
(639 mg, 4.62 mmol), and potassium iodide (768 mg, 4.62 mmol)
were stirred overnight at 75 °C in 8 mL of dry DMF. The reaction was
quenched with water, extracted twice with ethyl acetate, washed with
brine, and dried over Na2SO4, and the solvent was evaporated in
vacuo. The crude yellow oil was puriﬁed using ﬂash column
chromatography (15−25% EtOAc/hex), and the desired product
was obtained (170 mg, 0.542 mmol, 46.9% yield) as a yellow oil. 1H
NMR (CDCl3) δ 6.87−6.69 [3H, m, CHAR], 4.76 [2H, dt, J = 47 and
4.1 Hz, (OCH2CH2F)], 4.20 [2H, dt, J = 27 and 4.3 Hz,
(OCH2CH2F)], 3.86 [3H, s, OCH3], 3.35 [2H, q, J = 6.4 Hz,
NHCH2], 2.74 [2H, t, J = 7.1 Hz, NHCH2CH2], 1.43 [9H, s,
C(CH3)3];
13C NMR (CDCl3) δ 155.84, 149.78, 146.4, 132.88,
120.71, 114.61, 112.65, 81.32, 68.7, 68.54, 55.91, 41.81, 35.77, 28.39;
ESI-HRMS calculated for C16H24FNO4 313.1689, found 314.1678 [M
+ H]+, 336.1504 [M + Na]+.
2-(4-(2-Fluoroethoxy)-3-methoxyphenyl)ethanamine (8). tert-
Butyl 4-(2-ﬂuoroethoxy)-3-methoxyphenethylcarbamate (6, 200 mg,
0.638 mmol) was dissolved in 4 mL of DCM and 4 mL of TFA and
stirred at room temperature for 3 h. The solvent was evaporated in
vacuo, and the crude product was puriﬁed using ﬂash column
chromatography (15−20% MeOH/DCM) to obtain the desired
product (125 mg, 0.586 mmol, 92.0%) as white crystals. 1H NMR
(DMSO-d6) δ 6.93−6.76 [3H, m, CHAR], 4.71 [2H, dt, J = 48 and 3.8
Hz, CH2F], 4.17 [2H, dt, J = 30 and 3.9 Hz, OCH2], 3.77 [3H, s,
CH3], 3.03 [2H, t, J = 6.7 Hz, H2NCH2], 2.77 [2H, t, J = 6.7 Hz,
H2NCH2CH2];
13C NMR (CDCl3) δ 149.82, 146.84, 129.87, 120.63,
114.61, 112.47, 82.47, 81.11, 55.69, 40.62, 32.90; ESI-HRMS
calculated for C11H16FNO2 213.1165, found 214.1238 [M + H]
+.
2-(4-(2-((tert-Butoxycarbonyl)amino)ethyl)-2-methoxyphenoxy)-
ethyl 4-Methylbenzenesulfonate (5). tert-Butyl 4-hydroxy-3-methox-
yphenethylcarbamate (4, 613 mg, 2.29 mmol) was dissolved in 15 mL
of DMF, and ethane-1,2-diyl bis(4-methylbenzenesulfonate) (849 mg,
2.29 mmol) and cesium carbonate (149 mg, 4.59 mmol) were added.
The reaction mixture was stirred at room temperature for 3 h,
quenched with water, extracted with EtOAc, washed with brine, and
dried over Na2SO4. The solvent was removed in vacuo, and crude
product was puriﬁed using ﬂash column chromatography (15−35%
EtOAc/hex) to obtain the desired product as a white solid (440 mg,
0.945 mmol, 41% yield). 1H NMR (CDCl3) δ 7.82 [2H, d, J = 8.2 Hz,
OTs], 7.33 [2H, d, J = 8.2 Hz, OTs], 6.76−6.68 [3H, m, CHAR], 4.35
[2H, t, J = 5.0 Hz, (OCH2CH2OTs)], 4.19 [2H, t, J = 5.0 Hz,
(OCH2CH2OTs)], 3.81 [3H, s, OCH3], 3.33 [2H, q, J = 6.6 Hz,
NHCH2], 2.72 [2H, t, J = 6.8 Hz, NHCH2CH2], 2.44 [3H, s,
SC6H4CH3], 1.43 [9H, s, C(CH3)3];
13C NMR (CDCl3) δ 155.83,
149.82, 145.97, 144.85, 133.26, 132.78, 129.81, 128.01, 120.75, 115.21,
112.71, 68.1, 67.12, 60.39, 55.86, 41.81, 35.77, 28.39, 21.66; ESI-




methoxyphenoxy)ethyl 4-methylbenzenesulfonate (440 mg, 0.945
mmol) was dissolved in 5 mL of DCM and 5 mL of TFA and stirred
for 30 min at room temperature. The solvent was evaporated, and the
crude product was puriﬁed on ﬂash column chromatography (5−10%
MeOH/DCM) to obtain the puriﬁed product 2-(4-(2-aminoethyl)-2-
methoxyphenoxy)ethyl 4-methylbenzenesulfonate (350 mg, 0.958
mmol, quantitative yield) as a white powder. 1H NMR (MeOD) δ
7.81 [2H, d, J = 8.4 Hz, OTs], 7.42 [2H, d, J = 8.4 Hz, OTs], 6.88−
6.74 [3H, m, CHAR], 4.32 [2H, m, (OCH2CH2OTs)], 4.15 [2H, m,
(OCH2CH2OTs)], 3.82 [3H, s, OCH3], 3.15 [2H, q, J = 6.6 Hz,
NHCH2], 2.88 [2H, t, J = 7.1 Hz, NHCH2CH2], 2.45 [3H, s,
SC6H4CH3];
13C NMR (MeOD) δ 151.78, 148.41, 146.64, 134.46,
132.07, 131.19, 129.21, 122.25, 116.79, 114.32, 70.33, 68.66, 56.66,
42.12, 34.32, 21.74; ESI-HRMS calculated for C18H23NO5S 365.1297,
found 366.1435 [M + H]+.
(R)-2-(4-(2-((tert-Butoxycarbonyl)(4-cyano-4-(3,4-dimethoxy-
phenyl)-5-methylhexyl)amino)ethyl)-2-methoxyphenoxy)ethyl 4-
Methylbenzenesulfonate (13). Na2SO4 and (R)-2-(3,4-dimethoxy-
phenyl)-2-isopropyl-5-oxopentanenitrile (12, 151 mg, 0.547 mmol) in
2.5 mL of DCE were added to a solution of 2-(4-(2-aminoethyl)-2-
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methoxyphenoxy)ethyl 4-methylbenzenesulfonate (7, 300 mg, 0.821
mmol) in 2.5 mL of DCE. The reaction mixture was stirred at room
temperature overnight under argon. Sodium triacetoxyhydroborate
(174 mg, 0.821 mmol) was added to the mixture, and the mixture was
stirred for 1.5 h at room temperature. The reaction was quenched with
1 M NaHCO3, extracted with EtOAc (15 mL), washed with water
(2×) and brine, and the organic layers were dried over Na2SO4 and
used as such in the next step. Di-tert-butyl dicarbonate (239 mg, 1.095
mmol) and triethylamine (152 μL, 1.09 mmol) were added to the
diluted reaction mixture, and the mixture was stirred at room
temperature for 1.5 h. The reaction mixture was diluted with EtOAc,
washed with water and brine, and dried over Na2SO4, and solvent was
removed in vacuo. The crude mixture was puriﬁed by ﬂash column
chromatography (30−50% EtOAc/hexane) to obtain the puriﬁed
product as colorless oil (174 mg, 0.240 mmol, 43.9% yield). 1H NMR
(CDCl3) δ 7.82 (2H, d, J = 8.0 Hz, OTs), 7.33 (2H, d, J = 8.0 Hz,
OTs), 6.89−6.61 (6H, m, CHAR), 4.34 [2H, t, J = 4.9 Hz,
(OCH2CH2OTs)], 4.18 [2H, t, J = 5.0 Hz, (OCH2CH2OTs)], 3.88
(3H, s, OCH3), 3.86 (3H, s, OCH3), 3.79 (3H, s, OCH3), 3.25−2.99
(4H, m, CH2NCH2), 2.67 (2H, t, J = 6.5 Hz, NCH2CH2Ar), 2.44 (3H,
s, TsCH3), 2.05 (2H, m, CH2CH2CH2), 2.04−1.54 (3H, m,
CH(CH3)2 and CCH2), 1.42 (9H, m, Boc),, 1.17 and 0.78 (3H
each, d, J = 6.7 Hz, CH(CH3)2);
13C NMR (CDCl3) δ (ppm) 149.69,
148.93, 148.2, 145.85, 145.78, 144.82, 133.42, 132.71, 130.34, 129.78,
127.95, 121.31, 120.73, 118.63, 115.18, 112.75, 110.95, 109.24, 79.35,
68.09, 67.07, 55.89, 55.81, 55.79, 49.06, 48.66, 47.27, 37.84, 35.13,
34.77, 28.34, 24.58, 21.61, 18.89, 18.50; ESI-HRMS calculated for
C39H52N2O9S 724.3394, found 725.3477 [M + H]
+ and 747.3318 [M
+ Na]+.
(R)-2-(3,4-Dimethoxyphenyl)-5-((4-(2-ﬂuoroethoxy)-3-
methoxyphenethyl)amino)-2-isopropylpentanenitrile (2). To a
solution of (R)-2-(3,4-dimethoxyphenyl)-2-isopropyl-5-oxopentaneni-
trile (12, 108 mg, 0.392 mmol) in 5 mL of dry MeOH were added
Na2SO4 (167 mg, 1.18 mmol) and 2-(4-(2-ﬂuoroethoxy)-3-
methoxyphenyl)ethanamine (8, 125 mg, 0.588 mmol) under argon
and stirred overnight at room temperature. Sodium triacetoxyhy-
droborate (125 mg, 0.588 mmol) was added, and the mixture was
stirred for 2 h at room temperature under argon. The reaction was
quenched with saturated NaHCO3 and diluted with ether, and the
crude mixture was ﬁltered. The ﬁltrate was washed with brine and
dried over Na2SO4 and the solvent was removed in vacuo. The crude
product was puriﬁed by ﬂash column chromatography (1−10%
MeOH/DCM) to obtain the desired product as an oil (20 mg, 0.042
mmol, 10% yield). 1H NMR (CDCl3) δ 6.93−6.66 [6H, m, CHAR],
4.74 [2H, m, CH2CH2F], 4.22 [2H, m, CH2CH2F], 3.87, 3.85, and
3.82 [9H, 3xs, OCH3], 2.80 [4H, m, CH2NHCH2CH2], 2.67 [2H, m,
NHCH2CH2], 2.06 [1H, m, CH(CH3)2], 2.16 and 1.88 [1H each, dt, J
= 4.6 and 13 Hz, CCH2], 1.61 and 1.23 [1H each, m, CH2CH2CH2],
1.15 and 0.76 [3H each, d, J = 7 Hz, CH(CH3)2];
13C NMR (CDCl3)
δ (ppm) 149.74, 148.96, 148.23, 146.41, 132.52, 130.13, 121.2, 120.52,
118.59, 114.51, 112.53, 110.97, 109.31, 82.61, 81.25, 68.61, 68.44,
55.94, 55.88, 55.79, 49.90, 48.35, 37.85, 35.21, 34.42, 24.58, 18.86,
18.53; ESI-HRMS calculated for C27H37FN2O4 472.2737, found [M +
H]+ 473.2745.
(R)-5-((3,4-Dimethoxyphenethyl)(2-ﬂuoroethyl)amino)-2-(3,4-di-
methoxyphenyl)-2-isopropylpentanenitrile (1). To a solution of (R)-
5-((3,4-dimethoxyphenethyl)amino)-2-(3,4-dimethoxyphenyl)-2-iso-
propylpentanenitrile (74 mg, 0.17 mmol) in 2 mL of DMF, 1-bromo-
2-ﬂuoroethane (500 μL, 6.72 mmol) and potassium carbonate (255
mg, 1.85 mmol) were added, and the mixture was stirred at 65 °C for 4
h. The reaction mixture was extracted with EtOAc, washed with water
and brine, and dried over Na2SO4, and the solvent was removed in
vacuo. The crude product was puriﬁed by ﬂash column chromatog-
raphy (0−1% MeOH/DCM) to obtain the desired product as an oil
(40 mg, 0.082 mmol, 49% yield). 1H NMR (CDCl3) δ 6.91−6.66 [6H,
m, CHAR], 4.46 [2H, m, CH2CH2F], 3.89, 3.88, 3.86, and 3.85 [12H,
4xs, OCH3], 2.81−2.62 [6H, m, CH2N(CH2)CH2CH2], 2.54 [2H, m,
NCH2CH2], 2.05 [1H, m, CH(CH3)2], 2.12 and 1.85 [1H each, dt, J =
4.3 and 13 Hz, CCH2], 1.52 and 1.15 [1H each, m, CH2CH2CH2],
1.18 and 0.79 [3H each, d, J = 6.7 Hz, CH(CH3)2];
13C NMR
(CDCl3) δ (ppm) 148.96, 148.78, 148.23, 147.28, 132.8, 130.6,
121.47, 120.5, 118.64, 112.04, 111.17, 111.02, 109.57, 83.25, 81.92,
56.36, 55.95, 55.88, 55.84, 55.80, 53.92, 53.70, 53.3, 37.93, 35.41,
32.98, 23.35, 18.91, 18.57; ESI-HRMS calculated for C28H39FN2O4
486.2894, found 487.2975 [M + H]+.
Radiochemistry. (R)-5-((3,4-Dimethoxyphenethyl)(2-[18F]-
ﬂuoroethyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentaneni-
trile ([18F]1). [18F]F− was produced by the 18O(p,n)18F nuclear
reaction using an IBA (Louvain-la-Neuve, Belgium) Cyclone 18/9
cyclotron. Radioactivity levels were measured using a Veenstra (Joure,
The Netherlands) VDC-405 dose calibrator. Radiochemistry was
carried out in homemade, remotely controlled synthesis units.29 After
irradiation, [18F]ﬂuoride was trapped on a PS-HCO3 column and
eluted with 1 mL of MeCN/H2O (9:1, v/v) containing 13 mg (35
μmol) of Kryptoﬁx 2.2.2 and 2 mg (14 μmol) of K2CO3 into a screw
cap reaction vial. The [18F]K222/KF/K2CO3 complex was dried at 90
°C under a helium ﬂow of 50 mL·min−1 and reduced pressure for 6
min. MeCN (0.5 mL) was added, and the complex was dried for 3 min
resulting in a white tarnish at the bottom of the vial. 2-
Bromoethyltosylate (10 mg, 36 μmol) was dissolved in 0.5 mL of
DMF and added to the vial containing the dried complex, and this
reaction mixture was heated to 90 °C. After 10 min, the formed
volatile intermediate 1-bromo-2-[18F]ﬂuoroethane was distilled at 100
°C through a preheated silver triﬂate column at 200 °C resulting in
[18F]ﬂuoroethyltriﬂate, which was bubbled to the second reaction vial
containing a reaction mixture with 1.5 mg (3.4 μmol) of (R)-
desmethyl-norverapamil, 1.5 mg (11 μmol) of K2CO3, and a stirring
bar in 0.5 mL of ACN at 0 °C (Scheme 4). After distillation, the
reaction was stirred for 15 min at 120 °C, quenched with 1 mL of
water, and puriﬁed by semipreparative HPLC (method E). The
product eluted at 8 min and was collected for 1.5 min, and the fraction
was diluted with 40 mL of water. The mixture was passed through a
Sep-Pak Plus tC18 cartridge and subsequently rinsed with 20 mL
water. The product was eluted from the Sep-Pak Plus tC18 cartridge
with 1 mL of ethanol (96%). The ﬁnal product containing [18F]1 was
diluted with a solution of 7.11 mM NaH2PO4 in 0.9% NaCl (w/v in
water), pH 5.2, resulting in a ﬁnal solution with 5% ethanol. The purity
was >95%, and the speciﬁc activity was 143 ± 88 GBq/μmol, which
was derived from a calibration curve of reference compound 1 using
HPLC (methods A and B). In the end, 400−1600 MBq was isolated,
and the overall radiochemical yield was 2.7% ± 1.2% DC, starting from
20 to 50 GBq [18F]F− (n = 7).
(R)-2-(3,4-Dimethoxyphenyl)-5-((4-(2-[18F]ﬂuoroethoxy)-3-
methoxyphenethyl)amino)-2-isopropylpentanenitrile ([18F]2). The
[18F]K222/KF/K2CO3 complex was dried as described above, 1.0 mg of
precursor 13 in 0.5 mL of MeCN was added to the reaction vial, and
the reaction mixture was heated at 90 °C for 15 min. The reaction
mixture was cooled down to room temperature, and 0.2 mL of TFA
was added. After 10 min, the reaction was quenched with 0.9 mL of 2.5
M NaOH and puriﬁed by semipreparative HPLC (method F). The
product eluted at 15 min and was collected for 1.5 min, and the
fraction was diluted with 40 mL of water. The mixture was passed
through the Sep-Pak Plus tC18 cartridge and subsequently rinsed with
20 mL water. The product [18F]2 was eluted with 1 mL of ethanol
(96%) and diluted with a solution of 7.11 mM NaH2PO4 in 0.9% NaCl
(w/v in water), pH 5.2, resulting in a ﬁnal solution with 5% ethanol
with a purity of >95%. The speciﬁc activity was 151 ± 74 GBq/μmol,
which was derived from a calibration curve of reference compound 2
using HPLC (method C). At the end of the synthesis, 300−8000 MBq
was isolated, and the overall radiochemical yield was 17.2% ± 9.9%
DC, starting from 15−50 GBq [18F]F− (n = 7).
(R)-[11C]Verapamil. Radiolabeling of (R)-[11C]verapamil was
performed as described previously.30 The product was puriﬁed by
semipreparative HPLC (method E) with a retention time of 10 min.
The collected HPLC fraction was diluted with 40 mL of water and the
mixture was passed through a Sep-Pak Plus tC18 cartridge and
subsequently rinsed with 20 mL of water. The product was eluted with
1 mL of ethanol (96%) and diluted with a solution of 7.11 mM
NaH2PO4 in 0.9% NaCl (w/v in water), pH 5.2, resulting in a ﬁnal
solution with 5% ethanol, with a purity of >95% and a speciﬁc activity
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of 118 GBq/μmol (n = 1) as determined on HPLC (method B). At
the end of the synthesis, 5.2 GBq was isolated, and overall
radiochemical yield was 28.2% DC, starting from 60 GBq [11C]CO2
(n = 1).
Log D7.4. The distribution of [
18F]1 and [18F]2 between equal
volumes of 0.2 M phosphate buﬀer (pH 7.4) and 1-octanol was
measured in triplicate at room temperature. One milliliter of a 1−5
MBq/mL solution of [18F]1 or [18F]2 in 0.2 M phosphate buﬀer (pH
7.4) was vigorously mixed with 1 mL of 1-octanol for 1 min at room
temperature using a vortex. After 30 min, ﬁve samples of 100 μL were
taken from both layers, avoiding cross-contamination. To determine
recovery, 5 samples of 100 mL were taken from the 1−5 MBq/mL
solution. All samples were counted for radioactivity. The log Doct,7.4
value was calculated according to log Doct,7.4 =
10log(Aoct/Abuffer), where
Aoct and Abuffer represent average radioactivity of 5 1-octanol and 5
buﬀer samples, respectively.31
Animals. Healthy male Wistar rats were obtained from Harlan
Netherlands B.V. (Horst, the Netherlands) and male wild-type mice,
Mdr1a/b(−/−) mice, and Bcrp1(−/−) mice developed from the FVB line
were purchased from Taconic (Hudson, USA). All animals were
housed in groups of four to six per cage until treatment and were kept
at room temperature of 20−24 °C with a relative humidity of 50−70%
and under a 12 h light/dark cycle. Animals had unrestricted access to
food (Teklad Global 16% Protein Rodent Diet, Harlan, Madison, WI,
USA) and tap water. All animal experiments were performed in
compliance with Dutch laws on animal experimentation and after
approval by the local animal ethics committee.
Biodistribution. Healthy Wistar rats (218−244 g) were injected
with 50 ± 2 MBq of either [18F]1 or [18F]2 in the tail vein under
isoﬂurane anesthesia (2% in O2 at 1 L·min
−1). Rats were conscious for
the allowed time between injection and sacriﬁcing, except for the
animals of the 5 min time point, which were left unconscious for the
whole time. Animals were sacriﬁced under isoﬂurane anesthesia at time
points 5, 15, or 60 min (n = 3). Blood was collected via a heart
puncture from each rat. Heart, lungs, liver, kidneys, bone, cerebral
cortex, cerebellum, and the rest of the brain were collected, weighed,
and counted for radioactivity in a Wallac Universal Gamma Counter
1282 (PerkinElmer, Waltham, MA, USA). Biodistribution data were
expressed as percentage injected dose per gram tissue (%ID/g).
Metabolite Analysis. Healthy Wistar rats (230−291 g) were
injected with 28 ± 4 or 43 ± 24 MBq of [18F]1 or [18F]2, respectively,
in the tail vein under isoﬂurane anesthesia. After injection, rats were
conscious for the allowed time and sacriﬁced under isoﬂurane
anesthesia at time point 5, 15, or 60 min (n = 3). Blood samples
were collected via heart puncture, and the brain was removed from the
skull and cut in half. Blood was collected in a heparin tube and
centrifuged for 5 min at 4000 rpm (Hettich universal 16, Depex B.V.,
the Netherlands). Plasma was separated from blood cells, 1 mL was
loaded onto an Sep-Pak tC18 cartridge (Waters, Etten-Leur, the
Netherlands), and the cartridge was washed with 20 mL of water. This
eluate was deﬁned as the polar radiolabeled metabolite fraction. Next,
the Sep-Pak cartridge was eluted with 1.5 mL of methanol. This eluate
was deﬁned as the nonpolar fraction and contains the parent tracer.
This eluate was analyzed using HPLC (method G). The recovery from
the Sep-pak procedure was >85%, and remaining activity was not taken
into account. One half of the brain was counted for activity, and the
other half was homogenized with an IKA T18 ULTRA-TURRAX
Basic Homogenizer (IKA, Germany) in cold H2O/MeCN (1:1, v/v)
under ice cooling and subsequently centrifuged at 4000 rpm for 5 min.
Separated supernatants were analyzed using HPLC.
PET Imaging and Data Analysis. For all experiments, animals
were anesthetized via a nose mask initially using 4% isoﬂurane in
oxygen at a rate of 1 L/min. One hour prior to each study, a jugular
vein was cannulated for administration of the radiotracer. Rats were
positioned in pairs, and mice were scanned in groups of 4−6 using a
double LSO/LYSO layer High Resolution Research Tomograph
(HRRT; Siemens/CTI, Knoxville, TN, USA).32 During scanning,
anesthesia was maintained using 2% isoﬂurane in oxygen. For each
scanning session, ﬁrst a transmission scan was acquired using a 740
MBq two-dimensional (2D) fan-collimated 137Cs (662 keV) moving
point source.33 This scan was used to correct subsequent emission
scans for attenuation and scatter. As the HRRT was decommissioned,
the ﬁnal study (Mdr1a/b(−/−) vs WT mice of [18F]2) had to be
performed on nanoPET/CT and nanoPET/MR scanners (Mediso
Ltd., Budapest, Hungary)34 with identical PET components. In this
study, the CT scan was used for attenuation correction and the MR
scan for co-registration purposes. For the emission scans, Wistar rats
(341−450 g) were injected with 9.9 ± 3.2 MBq of [18F]1 (n = 4) or
9.9 ± 0.6 MBq of [18F]2 (n = 6) and scanned for 1 h. Next, a second
emission scan (30 min) following injection of 9.0 ± 1.7 MBq of
[18F]NaF was performed to delineate bone. The following day, the
same rats received an intravenous bolus injection of 15 mg/kg (3.5
mg/mL) tariquidar, dissolved in a vehicle consisting of 5% glucose in
saline. Thirty to forty minutes after tariquidar administration, rats were
injected with 9.8 ± 1.4 MBq of [18F]1 or 8.7 ± 0.5 MBq of [18F]2.
Again, this was followed by an [18F]NaF (7.9 ± 3.5 MBq) scan. [18F]1
and [18F]2 scans were acquired in list mode and rebinned into the
following frame sequence: 10 × 60, 4 × 300, and 3 × 600 s. The
[18F]NaF scans were processed as a single static scan. Mice (28.3−39.7
g) were injected with 3.6 ± 0.6 MBq of [18F]1 or 3.8 ± 0.4 MBq of
[18F]2 and scanned for 60 min. Emission scans were acquired in list
mode and rebinned into the following frame sequence: 7 × 10, 1 × 20,
3 × 30, 2 × 60, 2 × 150, 4 × 300, and 3 × 600 s for all HRRT scans.
For the nanoPET scans, the following frame sequence was used: 4 × 5,
4 × 10, 2 × 30, 3 × 60, 2 × 300, 3 × 600, and 1 × 900 s. Following
corrections for decay, dead time, scatter, and randoms, HRRT
emission scans were reconstructed using an iterative 3D-ordered
subset weighted least-squares algorithm (3D-OSWLS).33 The point
source resolution varied across the ﬁeld of view from approximately
2.3 to 3.2 mm full width at half-maximum in the transaxial direction
and from 2.5 to 3.4 mm in the axial direction. Reconstruction of the
nanoPET emission scans was performed using an iterative 3D Poisson
ordered-subset expectation-maximization algorithm (Tera-Tomo;
Mediso Ltd.34) with 4 iterations and 6 subsets, resulting in an
isoptropic 0.4 mm voxel dimension. PET images were analyzed using
the freely available AMIDE software (version 0.9.2).35 An MR based
rat brain atlas was used to deﬁne a whole brain region of interest in
rats. For each rat, this validated MR atlas was aligned visually with the
[18F]NaF image using a procedure described previously to obtain a
corresponding whole brain region of interest (ROI).36 Next, these
ROIs were projected onto the dynamic [18F]1 and [18F]2 image
sequence, generating whole brain time−activity curves (TACs). For
mice, ellipsoidal shaped ROIs were drawn manually over the brain.
Again, these ROIs were projected onto the dynamic image sequences,
generating whole brain TACs. All TACs were expressed as
standardized uptake values (SUV), that is, mean ROI radioactivity
concentration normalized to injected dose and body weight. In
addition, an ellipsoid was drawn over the complete animal (excluding
the cannula) to obtain the image derived percentage injected dose per
cc (%ID/cc). Finally, ellipsoid shaped ROIs manually drawn over the
left ventricle were used to obtain a blood curve. The area under the
curve (AUC) of the blood and brain curves were determined by
Graphpad PRISM (v 5.02, Graphpad Software Inc.) and brain-to-
blood AUC ratios were derived from these values.
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